We serve Chemical Name:Ethyl-N-methyl malonamide CAS:71510-95-7 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:Ethyl-N-methyl malonamide
CAS.NO:71510-95-7
Synonyms:Propanoic acid, 3-(methylamino)-3-oxo-, ethyl ester;2-carboethoxy-N-methyl-acetamide;Ethyl 3-(methylamino)-3-oxopropanoate;Malnsaeuremethylamidaethylester;N-metiletossicarbonilacetammide;ETHYL 1-METHYL AMIDOMALONATE;MFCD08458724;N1-ethyl-N1-methylmalonamide;ethyl N-methylamidomalonate;Monoethyl malonate formamide;N-METHYL-MALONAMIC ACID ETHYL ESTER;Ethyl-N-methyl malonamide;Ethyl-N-methyl;3-ethoxy-3-oxo-N-methyl-propionamide
Molecular Formula:C6H11NO3
Molecular Weight:145.156
HS Code:2924199090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:286.5±23.0 °C at 760 mmHg
Density:1.1±0.1 g/cm3
Index of Refraction:1.428
PSA:55.40000
Exact Mass:145.073898
LogP:-0.42
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Propanoic acid, 3-(methylamino)-3-oxo-, ethyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,3-ethoxy-3-oxo-N-methyl-propionamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-carboethoxy-N-methyl-acetamide Use and application,Malnsaeuremethylamidaethylester technical grade,usp/ep/jp grade.
Related News: For Franco Stevanato, tapping public markets will give the company the freedom to keep innovating as it enters the next chapter of its 70-plus-year history. strontium hydride manufacturers The client needed full development and product readiness with an extremely short supply of the API. In addition, the scale-up batch was small because of the low volume of product demands of their orphan drug. 1-(benzenesulfonyl)-6-chloroindole suppliers TULIP-2 assessed the effect of anifrolumab in reducing disease activity as measured by the BILAG-Based Composite Lupus Assessment (BICLA) scale. In TULIP-1, 457 eligible patients were randomised (1:2:2) and received a fixed-dose intravenous infusion of 150mg anifrolumab, 300mg anifrolumab or placebo every four weeks, N-Phenyl-2-aminonorbornane vendor & factory.
